LB Pharmaceuticals, Inc. (LBRX)
43.04
-1.80
(-4.01%)
USD |
NASDAQ |
Sep 15, 16:00
43.90
+0.86
(+2.00%)
After-Hours: 20:00
LB Pharmaceuticals Enterprise Value : 911.86M for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 911.86M |
| September 14, 2026 | 963.49M |
| September 11, 2026 | 957.46M |
| September 10, 2026 | 1.004B |
| September 09, 2026 | 1.045B |
| September 08, 2026 | 1.094B |
| September 04, 2026 | 1.093B |
| September 03, 2026 | 1.040B |
| September 02, 2026 | 1.097B |
| September 01, 2026 | 1.028B |
| August 31, 2026 | 1.033B |
| August 28, 2026 | 1.046B |
| August 27, 2026 | 1.051B |
| August 26, 2026 | 1.059B |
| August 25, 2026 | 1.077B |
| August 24, 2026 | 1.060B |
| August 21, 2026 | 1.043B |
| August 20, 2026 | 1.032B |
| August 19, 2026 | 1.081B |
| August 18, 2026 | 1.076B |
| August 17, 2026 | 1.003B |
| August 14, 2026 | 1.048B |
| August 13, 2026 | 947.14M |
| August 12, 2026 | 978.98M |
| August 11, 2026 | 977.54M |
| Date | Value |
|---|---|
| August 10, 2026 | 992.46M |
| August 07, 2026 | 1.054B |
| August 06, 2026 | 1.059B |
| August 05, 2026 | 968.94M |
| August 04, 2026 | 968.08M |
| August 03, 2026 | 906.13M |
| July 31, 2026 | 826.97M |
| July 30, 2026 | 850.48M |
| July 29, 2026 | 795.99M |
| July 28, 2026 | 679.54M |
| July 27, 2026 | 674.96M |
| July 24, 2026 | 681.55M |
| July 23, 2026 | 670.37M |
| July 22, 2026 | 705.36M |
| July 21, 2026 | 604.11M |
| July 20, 2026 | 563.67M |
| July 17, 2026 | 578.30M |
| July 16, 2026 | 554.78M |
| July 15, 2026 | 599.81M |
| July 14, 2026 | 595.80M |
| July 13, 2026 | 602.39M |
| July 10, 2026 | 622.47M |
| July 09, 2026 | 645.13M |
| July 08, 2026 | 657.46M |
| July 07, 2026 | 660.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals, Inc. | 5.291B |
| Neumora Therapeutics, Inc. | 91.75M |
| ANI Pharmaceuticals, Inc. | 1.891B |
| Corcept Therapeutics, Inc. | 11.66B |
| Veru, Inc. | 16.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.60M |
| Total Expenses (Quarterly) | 51.60M |
| EPS Diluted (Quarterly) | -1.712 |
| Earnings Yield | -6.93% |
| Normalized Earnings Yield | -6.939 |